𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models

✍ Scribed by Young-Soon Na; Kyung-Ah Jung; Seung-Mi Kim; Yong Sang Hong; Min-Hee Ryu; Se Jin Jang; Dae Hyuk Moon; Dong-Hyung Cho; Jin Cheon Kim; Jung Shin Lee; Tae Won Kim

Publisher
Springer
Year
2010
Tongue
English
Weight
874 KB
Volume
68
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Activity of the histone deacetylase inhi
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
✍ Xiaozhong Qian; Gulshan Ara; Evan Mills; William J. LaRochelle; Henri S. Lichens πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 751 KB

## Abstract Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer agents. In the current investigation, we examined the activity of the HDACi belinostat in preclinical models of prostate cancer. __In vitro__ proliferation assays demonstrated that belinostat potently i

In vivo and in vitro antitumor activity
In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer
✍ Ada Rephaeli; Diana Blank-Porat; Nataly Tarasenko; Michal Entin-Meer; Inesa Levo πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 French βš– 553 KB

## Abstract AN‐7, a prodrug of butyric acid, induced histone hyperacetylation and differentiation and inhibited proliferation of human prostate 22Rv1 cancer cells __in vitro__ and __in vivo.__ In nude mice implanted with these cells, 50 mg/kg AN‐7 given orally thrice a week led to inhibition of tum